Biomarkers.

Background: Insight into APOE-mediated pathways is important to unravel pathophysiology and identify therapeutic targets against late-life cognitive decline and dementia. However, ante-mortem studies on the mediated effect of APOE on cognition and dementia through different disease markers on structural brain imaging remain scarce, in particular for APOE-ε2.

Method: We included all dementia-free participants from the population-based Rotterdam Study, who routinely underwent cognitive assessment and brain MRI between 2005-2009, and were followed-up for incident dementia until 1-1-2020.

Biomarkers.

Background: Hippocampal volume is an acknowledged biomarker of neurodegenerative disease, including Alzheimer's disease (AD). However, the relationship between other subcortical brain structures and dementia risk is uncertain and may differ by disease stage. We aimed to assess the prognostic value of subcortical volumes for dementia risk across different disease stages by investigating memory clinic-based populations and community-dwelling individuals.

Alzheimer's Imaging Consortium.

Background: Hippocampal volume is an acknowledged biomarker of neurodegenerative disease, including Alzheimer's disease (AD). However, the relationship between other subcortical brain structures and dementia risk is uncertain and may differ by disease stage. We aimed to assess the prognostic value of subcortical volumes for dementia risk across different disease stages by investigating memory clinic-based populations and community-dwelling individuals.

Dementia Care Practice.

Background: Treatment with monoclonal antibodies against amyloid-β slowed cognitive decline in recent randomized clinical trials in patients with mild cognitive impairment (MCI) and early dementia due to Alzheimer's disease (AD). However, trial eligibility criteria may affect generalizability to clinical practice.

Methods: We extracted eligibility criteria for trials of aducanumab, lecanemab and donanemab from published reports, and applied these to participants with MCI and early clinical AD dementia from the population-based Rotterdam Study.

Characterizing TIA and stroke symptomatology in a population-based study: implications for and diagnostic value of FAST-based public education.

Background: Urgent medical treatment is crucial after stroke and transient ischemic attack (TIA), but hindered by extensive prehospital delays. Public education campaigns based on FAST (Face-Arm-Speech-Time) have improved response after major stroke, but not minor stroke and TIA. We aimed to provide strategies to improve public education on a national level, by characterizing TIA and stroke symptoms in a population-based cohort, and extrapolating findings to the general Dutch population.